UNSPSC 51351804: Estrogens conjugated

This classification denotes a therapeutic progestin with the molecular formula C18H21NaO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IU5QR144QX but generally known as conjugated estrogens, which bears US NIH Compound Identifier 45357473. European Medicines Agency schedules trioxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB36355. SMILES: CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+].

UNSPSC 51351804 Estrogens conjugated, a Commodity code, addresses procurement of conjugated estrogen pharmaceutical products by state and local health authorities, primarily departments of health, corrections, and Medicaid agencies purchasing for clinical and institutional use. State and local governments buy conjugated estrogens as hormone replacement therapy and for treatment of menopausal symptoms, urogenital atrophy, and certain cancer indications within correctional facilities, public hospitals, and state health department clinics. Issuing bodies typically include state departments of corrections, state Medicaid programs, county health departments, and public hospital systems that stock pharmaceuticals for inpatient and outpatient populations. Purchasing occurs through both direct buys and cooperative purchasing agreements that allow smaller jurisdictions to leverage volume pricing negotiated by larger state systems.

The source provides no recent state and local contract opportunities tagged to this Commodity code. Without posted solicitation activity in the most-recent-opportunities block, current demand signals and geographic concentration cannot be characterized from available data. Procurement professionals should monitor state Medicaid, corrections, and public health RFQ and ITB channels directly, as pharmaceutical commodities are frequently purchased through standing cooperative agreements or renewal notices that may not appear in open-market solicitation streams.